International Stem Cell Corporation, announces that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human “parthenogenetic” stem cells from unfertilized eggs. Parthenogenetic stem cells not only solve ethical problems, but also promise to minimize immune-rejection by providing cells that can be immune-matched to large segments of the population.
These products represent milestone
CD133 (Prominin) is widely used as a marker for the identification and isolation of neural precursor cells from normal brain or tumor tissue. However, the assumption that CD133 is expressed constitutively in neural precursor cells has not been examined.
In this study, we demonstrate that CD133 and a second marker CD15 are expressed heterogeneously in uniformly undifferentiated human neural stem (NS) cell cultures. After fractionation by flow cytometry, clonogenic tripotent cells are found in populations negative or positive for either marker. We further show that CD133 is down-regulated at the mRNA level in cells lacking CD133 immunoreactivity. Cell cycle
Revolutionary as they may be, stem cells cannot escape the need for food. And until now, that food has represented a costly part of developing stem cells.
But that is about to change. The East Greenbush-based Neural Stem Cell Institute has developed a new substance that will substantially lower development costs.
“Stem cells are unstable,” as Christopher Fasano, the Institute’s director of research and development, says. He explains that they need a constant supply of food and a substance called a “growth factor,” or they start developing into different types of body tissues on their own, and cease being useful to
Image via Wikipedia
Embryonic stem cells (ESC) can survive even when inserted into chains of polymers, in a process in which they are “weaved” into artificial and flexible tissues able to adapt to various types of transplants. In an innovative technique, stem cells could be used in the future to produce artificial organs, say researchers at University College London.
The technique was described in a study, published in Integrative Biology. It implements other research to shape living cells into engineered tissues, including a technique which would print a live tissue using an ink printer, which would substitute normal ink
Patents offer the economic guarantees scientists and companies need to develop new treatments, Oliver Bruestle told Deutsche Welle. He’s at the center of a German court battle surrounding embryonic stem cell research
Oliver Bruestle, director of the Institute of Reconstructive Neurobiology at the University of Bonn, is pushing for Germany to recognize the right to patent procedures conducted on embryonic stem cells, saying patents are the right way to ensure that scientists and companies profit from their work.
Greenpeace, however, is opposed to the patents. The organization filed suit against a patent granted to Bruestle in 1999, saying that the patenting